Posted by Michael Wonder on 01 Apr 2024
US FDA accepts Astellas’ supplemental new drug application for Izervay (avacincaptad pegol intravitreal solution) for geographic atrophy
1 April 2024 - Target action date set for 19 November 2024.
Astellas Pharma today announced it received notification from the US FDA of acceptance of the company’s supplemental new drug application to include positive 2 year data in the US Prescribing Information for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy secondary to age-related macular degeneration.
